Leaders from venerable pharma companies, advocacy groups and life sciences organizations peer into the crystal ball ahead of the calendar's turn to 2024.
/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) today announced a collaboration and licensing.
/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazebâ„¢ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized.
First clinical data from ongoing Phase 1/2 trial show dose-dependent anti-tumor activity for investigational REGN5678 (PSMAxCD28) when combined with standard.